Figure 2

Effects of ISA27 on tumour growth in vivo. (A) To validate our in vitro results, we studied the effects of ISA27 in a cancer model in vivo. Tumour growth was measured twice a week by a caliper during all the treatment long (14 days of treatment). Intra-peritoneal treatment (IP: 5 mg Kg^–1) or low doses (LOW: 1 mg Kg^–1) of ISA27 retard tumour growth compared with controls. High doses (HIGH: 3 mg Kg^–1) are more effective, significantly reducing tumour size. Results are the mean of measurements from five mice per group (*P<0.05 vs control). The upper panel shows a representative image of tumours at the end of the treatment. (B) Tumours were homogenized and MDM2, p53, active caspase 3, and RB levels were analyzed. Actin was used as control. ISA27 induces an increase of p53 and cleaved caspase 3 levels and a reduction of p-RB expression in treated tumours compared with controls. MDM2 level were unchanged in treated tumours with respect to controls. Images are representative of three independent experiments.